China's Center for Drug Evaluation proposes breakthrough therapy designation for three non-small cell lung cancer drugs.

China's Center for Drug Evaluation (CDE) has proposed including three domestic innovative drugs, all targeting non-small cell lung cancer (NSCLC), in its breakthrough therapy program. The drugs include AnRun Medical Technology's AMX3009, CSPC Pharmaceutical Group's SYS6010, and Multitude Therapeutics' AMT-116, signaling potential advancements in precision oncology options for NSCLC patients in China.